Amgen issues $4.0B in senior notes across four tranches with maturities 2031-2056

AMGEN INC

Issued $1.0B 4.200% notes due 2031, $1.75B 4.850% notes due 2036, $500M 5.500% notes due 2046, $750M 5.650% notes due 2056.
Net proceeds of ~$3.96B after underwriting discounts and estimated offering expenses.
Interest payable semi-annually on Feb 19 and Aug 19, starting Aug 19, 2026.
Holders may require repurchase at 101% upon a change-in-control triggering event.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

AMGEN INC entered into Officer's Certificate valued at $1,000,000,000 aggregate principal amount of the Company’s 4.200% Senior Notes due 2031, $1,750,000, (effective 2026-02-19).

Action: entry
Agreement: notes offering
Value: $1,000,000,000 aggregate principal amount of the Company’s 4.200% Senior Notes due 2031, $1,750,000,
Effective: 2026-02-19

Exact text from the filing

On February 17, 2026, Amgen Inc. (the “Company”) issued and sold $1,000,000,000 aggregate principal amount of the Company’s 4.200% Senior Notes due 2031 (the “2031 Notes”), $1,750,000,000 aggregate principal amount of the Company’s 4.850% Senior Notes due 2036 (the “2036 Notes”), $500,000,000 aggregate principal amount of the Company’s 5.500% Senior Notes due 2046 (the “2046 Notes”) and $750,000,000 aggregate principal amount of the Company’s 5.650% Senior Notes due 2056 (the “2056 Notes” and, together with the 2031 Notes, the 2036 Notes and the 2046 Notes, the “Notes”).

View on SEC.gov

Browse all material agreements →

AMGEN INC filing history →

Source: SEC EDGAR

accession 0001193125-26-059490

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.